- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.12. | Vor Biopharma: Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design | 51 | GlobeNewswire (Europe) | Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue to... ► Artikel lesen | |
| 09.12. | Vor Biopharma Inc. - 8-K, Current Report | - | SEC Filings | ||
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 08.11. | Robert W. Baird Has Lowered Expectations for Vor Biopharma (NYSE:VOR) Stock Price | 1 | MarketBeat | ||
| 07.11. | Vor Biopharma Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 30.09. | Vor Bio ernennt neuen CFO | 1 | Investing.com Deutsch | ||
| 30.09. | Vor Bio appoints new CFO amid clinical advancements | 4 | Investing.com | ||
| 30.09. | Vor Biopharma: Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer | 188 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new... ► Artikel lesen | |
| 30.09. | Vor Biopharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.09. | Vor Biopharma-Aktie stürzt auf 52-Wochen-Tief von 0,69 US-Dollar | 5 | Investing.com Deutsch | ||
| 27.09. | Vor Biopharma stock plunges to 52-week low of $0.69 | 1 | Investing.com | ||
| 06.09. | What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday? | 2 | Benzinga.com | ||
| 06.09. | Vor Biopharma stock holds price target, buy rating on positive study data | 2 | Investing.com | ||
| 05.09. | Vor Bio stock rallies post-market on trem-cel study data | 2 | Seeking Alpha | ||
| 05.09. | Vor Bio reports promising AML treatment data | 1 | Investing.com | ||
| 05.09. | Vor Biopharma: New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies | 96 | GlobeNewswire (Europe) | Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with significant... ► Artikel lesen | |
| 30.08. | Vor Biopharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.08. | Vor Biopharma: Vor Bio to Participate in Upcoming Investor Conferences | 1 | GlobeNewswire (USA) | ||
| 09.08. | Vor Biopharma GAAP EPS of -$0.41 | 1 | Seeking Alpha | ||
| 08.08. | Vor Biopharma Inc. - 10-Q/A, Quarterly Report | 1 | SEC Filings | ||
| 08.08. | Vor Biopharma Inc. - 10-Q, Quarterly Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,110 | -17,16 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,364 | -0,27 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 9,900 | +2,06 % | Ginkgo Bioworks eligible for $9.4M in partnership for bioelectronic devices | ||
| RECURSION PHARMACEUTICALS | 6,035 | -0,90 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,000 | +8,01 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,730 | 0,00 % | Oncolytics Biotech (TSE:ONC) Stock Price Up 14.5% - Here's What Happened | ||
| ARCTURUS THERAPEUTICS | 15,500 | +4,45 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,891 | +5,72 % | Assertio Holdings, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 17,400 | -2,68 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| SIGA TECHNOLOGIES | 5,930 | -1,66 % | SIGA Technologies Inc.: Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced | Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,340 | -0,27 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 16,400 | -0,61 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,735 | +11,04 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,895 | -2,85 % | Where Will Summit Therapeutics Be in 5 Years? | ||
| ARVINAS | 18,480 | +3,65 % | Arvinas, Pfizer Report Positive Data From Phase 1b Study Of Vepdegestrant Combination Therapy | NEW YORK CITY (dpa-AFX) - Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE), Tuesday announced preliminary data from the ongoing Phase 1b portion of the TACTIVE-U sub-study of Vepdegestrant in combination... ► Artikel lesen |
VOR BIOPHARMA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,873 Euro und damit -0,15 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.
